CAN-PDP: CANnabidiol for Parkinson’s Disease Psychosis
The CAN-PDP study is a research trial investigating whether Cannabidiol (CBD) is a safe and well-tolerated treatment for people with Parkinson’s Disease Psychosis. The study aims to find out if CBD can help reduce hallucinations, delusions, and other symptoms of psychosis in people with Parkinson’s Disease or Parkinson’s Disease Dementia.
CBD is a non-addictive part of the cannabis plant that may have antipsychotic properties. The trial is ongoing at NHS Lothian, and we are looking for people with Parkinson’s Disease or Parkinson’s Disease Dementia who have also been experiencing visual hallucinations or delusions, for at least one month. These may be visual hallucinations that the person experiences without realising they are not real. Participants must have a carer or study partner who can support them through the study, to be eligible to take part.
Those eligible to take part will attend 6 in-person visits to the Clinical Research Facility at the Western General Hospital (transport can be arranged). Participants will be randomly allocated to either receive Cannabidiol 400mg/day for the first 6 weeks, then increased to 800 mg/day for the last 6 weeks or to a matched placebo groups for the 12 week study period.
Further information regarding the study is available on the trial website from the study team at King’s College London or can be found by contacting us using the information below.
This study is open to recruitment
To find out more about this research study, please contact:
loth.sdcrn@nhs.scot
0131 537 3804
Key Staff
This study is looking at patients with Parkinson’s disease.
